Q

Quirino Memorial Medical Center | Clinical Trial Unit

Research site
(Unclaimed)
Location
J.P. Rizal Corner P. Tuazon Barangay Marilag, Quezon City, National Capital Region, Philippines
Site insights

Top conditions

COVID-19 (4 trials)

Human Influenza (2 trials)

Communicable Diseases (2 trials)

Infections (2 trials)

Cognitive Dysfunction (1 trial)

Top treatments

Aspirin
Ipratropium
C21
GT0918
Avibactam
Proxalutamide
Rivaroxaban
Astegolimab
MTZ
Vitamin K

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 14
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immuno...

Active, not recruiting
COVID-19
Biological: Recombinant COVID-19 vaccine (Sf9 cells)
Other: Placebo control

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Placebo
Drug: Astegolimab

This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2...

Enrolling
Influenza, Human
Infection Viral
Biological: Intermediate dose A/H2N3c + standard dose MF59
Biological: High dose A/H2N3c + standard dose MF59

This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately...

Active, not recruiting
Influenza, Human
Biological: licensed QIV1
Biological: licensed QIV2

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems